York-based Abingdon Health signs supply agreement for 10 million COVID-19 antigen tests with Taiwanese Arise Corporation

York-based Abingdon Health has signed a supply agreement with the Taiwanese Arise Corporation for 10 million COVID-19 antigen tests.

Arise was established in 1971 and is a company incorporated in Taiwan with business activities in Taiwan, Japan, Singapore and other Asian countries.

In a statement, Abingdon said: "Abingdon will be launching, in calendar Q3 (third quarter) of 2022, a new e-commerce site, which will feature a range of lateral flow self-tests and professional-use tests under the Abingdon Simply Test brand. The COVID-19 test is one of these Abingdon Simply Tests."

Hide Ad
Hide Ad

"Following execution of this Agreement the Company will receive a purchase order for 10 million tests. The purchase order will be subject to the Abingdon Simply Test receiving Taiwan Emergency Use Authorization (“EUA”).

In a statement, Abingdon said:  "Abingdon will be launching, in calendar Q3 (third quarter) of 2022, a new e-commerce site, which will feature a range of lateral flow self-tests and professional-use tests under the Abingdon Simply Test brand. The COVID-19 test is one of these Abingdon Simply Tests."In a statement, Abingdon said:  "Abingdon will be launching, in calendar Q3 (third quarter) of 2022, a new e-commerce site, which will feature a range of lateral flow self-tests and professional-use tests under the Abingdon Simply Test brand. The COVID-19 test is one of these Abingdon Simply Tests."
In a statement, Abingdon said: "Abingdon will be launching, in calendar Q3 (third quarter) of 2022, a new e-commerce site, which will feature a range of lateral flow self-tests and professional-use tests under the Abingdon Simply Test brand. The COVID-19 test is one of these Abingdon Simply Tests."
Read More
York-based Abingdon Health signs 'significant' contract to manufacture lateral f...

"Once EUA is achieved Arise will issue Abingdon Health an irrevocable and confirmed revolving letter of credit for full payment of each shipment under this Agreement. The EUA process is underway but Abingdon Health does not have visibility on the timing for the completion of the EUA application review process. Abingdon Health will confirm to investors as soon as the Company is informed that the process has concluded. The Abingdon Simply Test is being provided by Abingdon Health in collaboration with a manufacturing partner."

"As part of the supply agreement Arise Biotech also have an option to purchase a further 20 million Abingdon Simply Tests. Due to commercial confidentiality the purchase price of the tests is not being disclosed but Abingdon Health confirms that this is a material contract subject to EUA as described above."

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to have secured such a significant agreement with Arise Biotech for the supply of Abingdon Simply Test COVID-19 tests for Taiwan. We must be clear with investors that fulfilment of this order depends on the successful completion of the Taiwan EUA application process, and we will update investors as soon as we can on this.”

Hide Ad
Hide Ad

Samuel Chou, Chairman of Arise Corporation, commented: “We are greatly blessed with the opportunity to work with Abingdon Health, on our mission for global equitable access to diagnostics. May this project be yet another testimony of God’s grace.”

Related topics:
News you can trust since 1754
Follow us
©National World Publishing Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice